Chemistry:Dexloxiglumide
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C21H30Cl2N2O5 |
| Molar mass | 461.38 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Dexloxiglumide is a drug which acts as a cholecystokinin antagonist, selective for the CCKA subtype. It inhibits gastrointestinal motility and reduces gastric secretions, and despite older selective CCKA antagonists such as lorglumide and devazepide having had only limited success in trials and ultimately never making it into clinical use, dexloxiglumide is being investigated as a potential treatment for a variety of gastrointestinal problems including irritable bowel syndrome,[1] dyspepsia,[2] constipation[3] and pancreatitis,[4][5] and has had moderate success so far although trials are still ongoing.
References
- ↑ "Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study". The American Journal of Gastroenterology 100 (3): 652–63. March 2005. doi:10.1111/j.1572-0241.2005.41081.x. PMID 15743365.
- ↑ "Basic and clinical pharmacology of new motility promoting agents". Neurogastroenterology and Motility 17 (5): 643–53. October 2005. doi:10.1111/j.1365-2982.2005.00675.x. PMID 16185302.
- ↑ "Use of novel prokinetic agents to facilitate return of gastrointestinal motility in adult critically ill patients". Current Opinion in Critical Care 12 (4): 295–302. August 2006. doi:10.1097/01.ccx.0000235205.54579.5d. PMID 16810038.
- ↑ "CCK1 receptor antagonist, dexloxiglumide: effects on human isolated gallbladder. Potential clinical applications". Minerva Gastroenterologica e Dietologica 49 (3): 211–6. September 2003. PMID 16484960.
- ↑ "Role of CCK and potential utility of CCK1 receptor antagonism in the treatment of pancreatitis induced by biliary tract obstruction". British Journal of Pharmacology 153 (8): 1650–8. April 2008. doi:10.1038/bjp.2008.44. PMID 18297100.
 |  |
